Isomorphic Labs raises $2.1B for AI drug discovery

Isomorphic Labs, an Alphabet spinout, has raised $2.1 billion in Series B funding to advance AI-designed drugs toward clinical trials by the end of 2026. The capital will be used to expand its drug pipeline and push candidates into human testing. The company leverages artificial intelligence to accelerate drug discovery, aiming to reduce the time and cost of bringing new medicines to market. This significant investment underscores growing confidence in AI's potential to transform pharmaceutical research.